Tango Therapeutics (TNGX) Cash from Operations Growth (3y) (2023 - 2026)
Tango Therapeutics (TNGX) Cash from Operations Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 34.32% |
| 10 | Tango Therapeutics | 3.84 Bn | 3.68 Bn | - | -8.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8.32% |
| Dec 31, 2025 | -1.68% |
| Sep 30, 2025 | -16.43% |
| Jun 30, 2025 | -5.01% |
| Mar 31, 2025 | -12.02% |
| Dec 31, 2024 | -29.43% |
| Sep 30, 2024 | -15.82% |
| Jun 30, 2024 | -46.44% |
| Mar 31, 2024 | -40.63% |
| Dec 31, 2023 | -337.76% |
| Sep 30, 2023 | -603.88% |
| Jun 30, 2023 | -9,044.90% |